Metabolic engineering: the ultimate paradigm for continuous pharmaceutical manufacturing.

Area of Science:

• Pharmaceutical Manufacturing
• Chemical Synthesis
• Biotechnology

Background:

• Pharmaceutical R&D expenditures have doubled, yet attrition rates and development times have increased.
• Companies are shifting focus from R&D to manufacturing, exploring continuous manufacturing to access emerging markets.
• Current continuous manufacturing models involve flow reactors for API synthesis and solid processing for tablets.

Purpose of the Study:

• To evaluate the limitations of current continuous flow manufacturing in pharmaceutical production.
• To propose an alternative manufacturing strategy for accessing complex chemical spaces, including natural products.
• To investigate the potential of metabolic engineering as a core component of a novel manufacturing paradigm.

Main Methods:

• Analysis of current trends in pharmaceutical R&D and manufacturing expenditures.
• Critique of continuous flow synthesis limitations for complex molecule production.
• Proposal of a hybrid manufacturing approach integrating metabolic engineering with flow chemistry.

Main Results:

• Continuous flow synthesis, while improving yield and purity, does not overcome limitations in reaction scope or atom/energy economy for all APIs.
• Metabolic engineering is presented as a more effective and scalable strategy for producing oxidized scaffolds, serving as gateway molecules.
• This integrated approach allows for rapid optimization and facile scale-up from gram to ton quantities.

Conclusions:

• Metabolic engineering, as the engine of a new manufacturing paradigm, enables access to natural product chemical space.
• This approach recasts manufacturing as a tool for drug discovery, facilitating rapid optimization and scale-up.
• The proposed model offers a scalable solution for producing complex pharmaceutical ingredients, addressing limitations of current flow synthesis.